GOLDENWELL BIOTECH, INC. (GWLL) Form 10-Q — Jun 30, 2026

Goldenwell Biotech reported zero revenue and a net loss of $17,606 for the quarter ended March 31, 2026, with cash decreasing to $13,414 from $26,775 at year-end. The company remains in the development stage with no sales and estimates it needs approximately $5,000,000 to construct manufacturing facilities, though it has no financing arrangements in place. Management explicitly raised substantial doubt about the company's ability to continue as a going concern, citing its history of losses and reliance on raising capital. The filing also includes a restatement of the prior year's quarterly financials to correct a $4,160 legal fee accrual error identified by the auditor.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.